The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | The growing role of fixed-duration therapy in chronic lymphocytic leukemia
Inhye Ahn, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the growing role of fixed-duration treatment strategies in chronic lymphocytic leukemia (CLL). She explores the potential advantages of time-limited therapy with pirtobrutinib and obinutuzumab, and considers how evolving combination regimens and treatment breaks may shape frontline treatment selection in the years ahead.This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Where the field is going right now is to maximize efficacy as well as safety. So in order to maximize the efficacy, the field is testing doublet or triplet combinations in the upfront settings as well as the relapse refractory setting. In terms of maximization of the safety, the trials are now looking into the treatment breaks. And one of the approaches that we have taken in the specific trial of Pirtobrutinib and Acalabrutinib was to take an artificial break after about one year of therapy...
Where the field is going right now is to maximize efficacy as well as safety. So in order to maximize the efficacy, the field is testing doublet or triplet combinations in the upfront settings as well as the relapse refractory setting. In terms of maximization of the safety, the trials are now looking into the treatment breaks. And one of the approaches that we have taken in the specific trial of Pirtobrutinib and Acalabrutinib was to take an artificial break after about one year of therapy. So I think the more maturing data from these trials would be helpful for us to determine the future directions. In the U.S. setting right now, the treatments are largely divided into two methods. One is to use a continuous treatment with one of the BTK inhibitors, a more selective one. The other approach is combination over a fixed duration or MRD-guided duration of the time. And there are several combinations in that category.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
